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Abstract
Bacground: We have previously reported mid-term results of a study, which ended in January
2000, on the Bicarbon valve. The study concluded that the valve showed excellent clinical results,
associated with a low incidence of valve-related complications. In the present study, the same
patients were prospectively followed for an additional 5 years.
Methods: Forty-four patients had aortic valve replacement (AVR), 48 had mitral valve replacement
(MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105
patients was 61.2 ± 11.3 years. The mean follow-up was 6.1 ± 1.9 years with a cumulative follow-
up of 616 patient-years.
Results: There were 5 early deaths (4.7%: 4 in the AVR group and 1 in the MVR group) and 21
late deaths (3.4%/patient-year: 5 valve related deaths and 16 valve unrelated deaths). Survival at 8
years was 75.2 ± 7.0% in the AVR group, 76.6 ± 6.2% in the MVR group, and 55.4 ± 16.1% in the
DVR group. The linearized incidence of thrombo-embolic complications, hemorrhagic
complications, and paravalvular leaks in all patients was 0.65 ± 1.48%, 0.81 ± 1.69%, and 0.16 ±
0.54%/patient-year respectively. No other complications were observed.
Conclusion: The Bicarbon prosthetic heart valve has shown excellent long-term clinical results,
associated with a low incidence of valve-related complications.
Background
Both mechanical and bioprosthetic heart valves have
become more durable and less thrombogenic, possessing
excellent clinical outcomes and hemodynamic features.
However, lifelong anticoagulant therapy is inevitable for
patients with mechanical prosthetic valves, and those with
bioprosthetic valves have higher risks of structural valve
dysfunction than those with mechanical ones. In mechan-
ical valves, bileaflet prosthetic heart valves are more pref-
erably implanted than tilting disc valves, and surgeons
choose some of them for valve replacement according to
their own preference and the patients' informed consent.
Many long-term clinical results showed excellent clinical
performances of mechanical prostheses.
The Bicarbon valve (Sorin Biomedica Cardio, Saluggia,
Italy) was introduced for clinical application at our insti-
tute in 1997 [1]. The purpose of this study is to evaluate
prospective clinical performances of the Bicarbon valve
implanted at a single center in Japan.
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Methods
Between February 1997 and December 2000, 107 patients
were implanted with 120 Bicarbon valves at the Jichi Med-
ical University Hospital. Two of the patients were
excluded for the presence of two different types of valves,
because they had been already implanted with another
valve and received a Bicarbon valve in a different position.
Forty-four patients had aortic valve replacement (AVR),
48 had mitral valve replacement (MVR), and 13 had both
aortic and mitral valve replacement (DVR). There were 55
men and 50 women. Patients between the sixth and
eighth decade consisted of the main candidates, and the
mean age was 61.2 ± 11.3 years for all patients. The mid-
term results of 105 patients with a Bicarbon valve as of the
end of January 2000 have already been reported [2]. Clin-
ical data of the same patients was evaluated on the basis
of mortality and morbidity analysis until the end of
December 2005.
At the operation, the myocardium was protected by mod-
erate hypothermia, and by ante-grade with or without
retro-grade intermittent perfusion of blood cardioplegic
solution. For MVR, the posterior mitral valve apparatus
was preserved, and an anti-anatomical position was cho-
sen for implantation. Heparin sodium injection was our
usual postoperative care during the early postoperative
period, followed by oral anticoagulant therapy. Concom-
itant cardiac surgery procedures were tricuspid annulus
repair in 28 patients, coronary artery bypass grafting in 16,
maze procedure in 10, aortic root replacement in 6, and
others [2]. Three patients with AVR and 7 with MVR had
undergone valve surgery once or twice previously. Our
postoperative anticoagulant therapy consisted of both
warfarin potassium and anti-platelet agents such as dipy-
ridamole or aspirin. The INR (international normaliza-
tion ratio) jwas controlled to maintain values between 1.8
and 3.3 for patients having MVR and DVR, and was
between 1.3 and 1.8 for AVR patients before 2000. Since
then, INR was between 1.8 and 3.3 for all patients. For
patients with atrial fibrillation who have mechanical
valves, an INR of at least 2.5 is recommended. Thus, for
young patients, our criterion is based on the recommen-
dation, but for aged patients with some risk factors for cer-
ebral bleeding, an INR is below the level of the
recommendation [3].
Morbidity analysis included all cardiovascular complica-
tions as defined in Edmunds et al., Guidelines for Report-
ing Morbidity and Mortality after Cardiac Valve
Operations [4]. Mortality data and incidence of clinical
adverse events were analysed by means of the Kaplan-
Meier actuarial method. The probability of freedom from
the first occurrence of each complication was graphically
represented with regard to the follow-up time. Each
adverse event (death, thrombosis, embolism, anticoagu-
lant related bleeding, endocarditis, non structural dys-
function) was summarised by means of linearized rates,
calculated as the number of occurred events divided by
the total number of patient-years (cumulative follow-up).
This analysis was also conducted for re-operation events.
For each linearized rate, upper confidence limits (95%)
were provided, according to the method reported by
Grunkemeier and Anderson [5]. All analyses were per-
formed for the whole sample of data and stratified by
implant site (aortic, mitral, and both aortic and mitral).
For continuous variables descriptive statistics (mean,
standard deviation, range) were provided.
As of the end of December 2005, 105 patients had partic-
ipated in the follow-up study through an office interview,
personal phone call, or mail interview. All patients were
followed-up (100% completeness of follow-up) with a
mean follow-up of 6.1 ± 1.9 years overall (AVR, 6.3 ± 1.8
years; MVR, 6.1 ± 1.9 years; DVR, 5.6 ± 2.2 years) and a
cumulative follow-up of 616 years (257 years for AVR,
286 years for MVR, and 73 years for DVR).
Results
1. Freedom from mortality and morbidity
a) Survival and clinical functional class
Twenty-six patients died, including 5 hospital deaths (10
AVRs, 11 MVRs and 5 DVRs). One valve related death
occurred in the AVR group, 2 in the MVR group and 2 in
the DVR group. The survival rates at 8 years were 73.6 ±
4.5% overall, 75.2 ± 7.0% for AVR, 76.6 ± 6.2 % for MVR,
and 55.4 ± 16.1% for DVR (Fig. 1). Preoperatively, 91.4%
of the patients were in the New York Heart Association
(NYHA) functional class III or IV, and 96.8% were in class
I or II at follow-up.
b) Embolic events
Three embolic events occurred in the AVR group and 1 in
the DVR group as follows: 1 non-obstructive mesenteric
infarction, 1 transient ischemic cerebral accident and 2
strokes. The freedom from embolic episodes at 8 years was
95.8% overall, 93.6% in the AVR group, and 90.0% in the
DVR group (Fig. 2).
c) Thrombosis
No thrombotic episodes occurred in this study.
d) Anticoagulant related bleeding
Three bleeding episodes occurred in the MVR group; 2 for
gastric hemorrhage and 1 for fatal cerebral hemorrhage.
Two cerebral hemorrhage events (1 fatal) occurred in theJournal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
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DVR group. The freedom from anticoagulant related
bleeding at 8 years was 96.0% overall, 95.6% in the MVR
group, and 84.6% in the DVR group (Fig. 3).
e) Non-structural prosthetic valve dysfunction
One occurrence of non-structural dysfunction in the MVR
group for peri-prosthetic valvular leak required re-opera-
tion. The freedom from non-structural dysfunction at 8





One patient required re-operation for peri-prosthetic leak
in the MVR group. The freedom from re-operation at 8
years was 98.9% overall and 97.8% in the MVR group.
h) Valve related death
One valve related death occurred in the AVR group, 2
occurred in the MVR group and 2 occurred in the DVR
group. The freedom from valve related death at 8 years
was 94.6% overall, 97.4% in the AVR group, 95.1% in the
MVR group, and 56.6% in the DVR group (Fig. 5).
2. Linearized rates and upper confidence rates of events
(Table 1)
The linearized rates and 95% confidence rates of each
event overall were 0.65 ± 1.48%/patient-year for embolic
Survival curve Figure 1
Survival curve. Numerical values of the graph express numbers of patients at the time of follow-up. Abbreviations; AVR: aor-
tic valve replacement, MVR: mitral valve replacement, DVR: both aortic and mitral valve replacement.Journal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
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events, 0.81 ± 1.69%/patient -year for bleeding, 0.16 ±
0.84%/patient year for non-structural dysfunction, and
0.81 ± 1.69%/patient-year for valve related death. The lin-
earized and 95% confidence rates of the AVR group were
1.16 ± 3.01%/patient-year for embolic events and 0.39 ±
2.01%/patient-year for valve related deaths. The linear-
ized and 95% confidence rates of the MVR group were
0.35 ± 1.81%/patient-year for non-structural dysfunction,
1.05 ± 2.71%/patient-year for bleeding, and those of the
DVR group were 1.37 ± 7.10%/patient-year for thrombo-
embolic events, and 2.74 ± 8.77%/patient-year both for
bleeding and for valve related deaths.
Discussion
No structural valve dysfunction has been observed in
recently available mechanical heart valves. However, non-
structural mechanical valve dysfunction, and throm-
boembolic, or hemorrhagic episodes, still lead to compli-
cations after valve surgery. Some patients need
reoperation because of prosthetic valve dysfunction
caused by restricting prosthetic valve function valve with
thrombosis or pannus formation and peri-prosthetic val-
vular leaks with or without infective endocarditis [6,7].
Lowering thrombo-embolic episodes after implantation is
the key for success when a mechanical valve is invented.
The Bicarbon valve is composed of 2 leaflets convex
toward the annulus. The 2 lateral orifices and the central
orifice contribute to making the 3 blood streams through
the prosthesis. The valve is designed on the basis that the
blood flow through each of the 3 orifices is equal in
amount, parallel, and laminar, preventing turbulent
blood flow through the valve. Another important feature
of the Bicarbon valve is the hinge rolling action that per-
Freedom from all embolic events Figure 2
Freedom from all embolic events. Abbreviations; AVR: aortic valve replacement, MVR: mitral valve replacement, DVR: 
both aortic and mitral valve replacement.Journal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
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mits total flushing of the blood-exposed surfaces [8].
These structural features are supposed to lower thrombo-
embolic episodes and hemolysis after implantation [9].
Excellent early and midterm clinical results of the Bicar-
bon valve have been previously reported [2,10-15]. The
longer the follow-up periods are, the more reliable the
clinical results are. Long-term follow-up studies of the
valve are not enough to evaluate its clinical performance.
With regard to single center mid-term results, Goldsmith
and colleagues reported that the Bicarbon valve has a sat-
isfactory clinical performance with low complication rates
[14]. A multi-center study of the Bicarbon valve in Europe
with a mean follow-up of 2.2 +/- 1.5 years showed 5%
early deaths, and 4.4% late deaths [15]. This study also
showed that survival of all the patients was 87% 5 years
after the operation. The linearized incidence of valve
thrombosis was between 0.06 and 0.69%/patient-years
among the AVR, MVR and DVR groups, and that of
embolic episodes was between 1.13 and 2.14%/patient-
years. Bleeding complications occurred at the rate of 0.69
to 1.26%/patient-years.
Previous studies have shown that with long-term experi-
ence with the Bicarbon valve, freedom from valve throm-
bosis at 7 to 9 years was between 97 and 99.4%, that from
embolic episodes was between 64 and 93%, and that from
bleeding complications was between 82 and 98.6% [16-
18]. Freedom from endocarditis and nonstructural valve
dysfunction at 7 to 9 years was between 95 and 99% and
between 84 and 98.7%, respectively. Actuarial analysis at
7 to 9 years showed an overall survival between 63.9 and
88%.
Long-term clinical experience with St. Jude Medical and
Carbomedics bileaflet mechanical valves for AVR and
Freedom from anticoagulant related bleeding Figure 3
Freedom from anticoagulant related bleeding. Abbreviations; AVR: aortic valve replacement, MVR: mitral valve replace-
ment, DVR: both aortic and mitral valve replacement.Journal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
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MVR have shown that the rates of thrombosis were
between 0.73 and 3.4%/patient-year, and that the 10-year
freedom from thrombosis was between 77 and 94.2%
[19-25]. In addition, the rates of bleeding were between
0.52 and 2.7%/patient-year, and the 10-year freedom
from bleeding was between 77 and 96.4%. This means
that these bileaflet mechanical valves work well without
different clinical performances.
We reported our echocardiographic evaluation and mid-
term clinical experience with the Bicarbon bileaflet pros-
thetic heart valve in 1999 and 2002. The echocardio-
graphic study showed that 3 blood streams through the
prosthesis were equal in amount, and parallel with similar
flow velocity, indicating the hemodynamic superiority of
the prosthesis to other bileaflet valves [1]. The latter clini-
cal follow-up report described the clinical results of sur-
vival, and valve-related morbidity or mortality on the
basis of the valve, and concluded that similar results were
obtained to those of other mechanical valves associated
with a low incidence of valve-related morbidity and mor-
tality [2].
The present follow-up study gives additional evidence of
low rates of valve-related complications of the Bicarbon
valve, showing that the 8-year freedom from thrombo-
embolism was 93.6% in the AVR and 100% in the MVR
groups, and the 8-year freedom from bleeding was 100%
in the AVR and 95.6% in the MVR groups. The rate of
thrombo-embolism in the AVR group was 1.16%/patient-
year, and that of bleeding in the MVR group was 1.05%/
patient-year. Thrombo-embolic complications occurred
in patients of the AVR and DVR groups, whose anticoagu-
lant therapy was well controlled. All patients received
both warfarin potassium and anti-platelet agents. An INR
between 1.3 and 1.8 was our standard for patients who
Freedom from non-structural prosthetic valve dysfunction Figure 4
Freedom from non-structural prosthetic valve dysfunction. Abbreviations; AVR: aortic valve replacement, MVR: mitral 
valve replacement, DVR: both aortic and mitral valve replacement.Journal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
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had AVR before 2000. We have previously reported that
AVR patients tended to show higher incidences of lethal
hemorrhagic complications [26]. Thus, INR for these
patients was lower than INR for patients who had MVR or
DVR. However, our previous study implies that INR
should be maintained between 1.8 and 3.3 for all patients
Table 1: Linearized Rates of Events
OVERALL AVR MVR DVR
%/pt-yr 95% CR %/pt-yr 95% CR %/pt-yr 95% CR %/pt-yr 95% CR
All Embolic Events 0.65 1.48 1.16 3.01 0.00 1.37 7.10
Non Structural Dysfunction 0.16 0.84 0.00 0.35 1.81 0.00
Bleeding 0.81 1.69 0.00 1.05 2.71 2.74 8.77
Valve Related Death 0.81 1.69 0.39 2.01 0.70 2.24 2.74 8.77
Abbreviations;
OVERALL: all patients including AVR, MVR, and DVR patients
AVR: aortic valve replacement, MVR: mitral valve replacement, DVR: both aortic and mitral valve replacement
Pt-yr: patient year, CR: confidential rate
Freedom from valve related death Figure 5
Freedom from valve related death. Abbreviations; AVR: aortic valve replacement, MVR: mitral valve replacement, DVR: 
both aortic and mitral valve replacement.Journal of Cardiothoracic Surgery 2007, 2:8 http://www.cardiothoracicsurgery.org/content/2/1/8
Page 8 of 8
(page number not for citation purposes)
having mechanical valve replacement [2]. Hemorrhagic
complications occurred in 5 patients with MVR or DVR,
including 2 deceased cases because of cerebral bleeding.
Anticoagulant therapy was well controlled in these 2
cases. This might indicate an adverse influence of antico-
agulant therapy on the patients' prognosis in cases of
complications. Therefore, we believe that not only careful
anticoagulant therapy but adequate control of risk factors
such as hypertension and diabetes mellitus is required to
prevent lethal complications. Non-structural prosthetic
valve dysfunction due to peri-valvular leak was observed
in only one MVR patient. Operative findings showed a
small fistula, 3 mm in diameter, between the left ventricle
and atrium, which was located near the posterior fibrous
trigon. The patient had no apparent history of infective
endocarditis after initial valve replacement. Postoperative
NYHA clinical functional improvement was satisfactory in
all groups. Low cardiac output syndrome led to lethal
complications in those patients with advanced stage IV
NYHA classification. In order to obtain better clinical out-
comes, an operation before advanced clinical function
should be considered, and more intensive peri-operative
management may be mandatory for patients with far
advanced heart failure.
Conclusion
We analyzed the cases of 105 patients who received a
Bicarbon prosthetic heart valve implantation at the mitral
and/or aortic position. This long-term single center study
with a Bicarbon prosthetic heart valve shows excellent
clinical results associated with a low incidence of valve-
related mortality and morbidity.
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